Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
5
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 5 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Hyrimoz(Cf) Pen Adalimumab-Adaz | D | $7.9M | +2306% | 468 | $16,967 | $5,849.15 |
| Hyrimoz(Cf) Adalimumab-Adaz | D | $965K | n/a | 55 | $17,548 | $7,314.81 |
| Hyrimoz(Cf) Pen Crohn-Uc Start Adalimumab-Adaz | D | $382K | n/a | 20 | $19,110 | $7,962.36 |
| Hyrimoz(Cf) Pen Psoriasis Adalimumab-Adaz | D | $283K | n/a | 22 | $12,850 | $8,031.21 |
| Hyrimoz Pen Adalimumab-Adaz | D | $100K | n/a | 29 | $3,453 | $772.76 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.